Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a biopharmaceutical company focused on investigational therapies for neurodegenerative and endocrine diseases, and its news flow reflects the progress and setbacks typical of clinical-stage drug development. Company updates frequently highlight milestones in its pipeline, including avexitide for post-bariatric hypoglycemia (PBH), AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis (ALS), and AMX0318 as a long-acting GLP-1 receptor antagonist candidate.
Investors following AMLX news can expect regular announcements on clinical trial progress, such as enrollment status, early safety and tolerability data, and biomarker analyses from studies like the Phase 3 LUCIDITY trial in PBH and the Phase 1 LUMINA trial in ALS. Amylyx also issues press releases when it reports financial results, providing context on research and development spending, cash runway, and the anticipated timing of key clinical and regulatory milestones.
Another recurring news theme is regulatory and program updates, including FDA designations, decisions to advance or discontinue specific programs, and detailed descriptions of conditions such as PBH, ALS, PSP, and Wolfram syndrome. The company has, for example, communicated its decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results, while continuing development of AMX0035 in Wolfram syndrome.
Amylyx also announces capital markets events and investor outreach, such as underwritten public offerings of common stock and participation in healthcare and biopharma conferences. For readers tracking AMLX, this news page offers a consolidated view of clinical, financial, and strategic disclosures that shape the company’s development trajectory. Bookmarking this feed can help investors and observers monitor how Amylyx’ investigational therapies advance through trials and how management communicates key developments.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced significant preclinical data demonstrating that AMX0035, a combination of sodium phenylbutyrate and taurursodiol, has a pronounced effect on ALS-relevant molecular pathways compared to individual components. The published study in Annals of Clinical and Translational Neurology showed AMX0035 altered more genes and metabolites in fibroblasts from ALS patients than either compound alone. This underscores its potential benefits in treating ALS, a disease affecting over 90% of ALS patients.
Amylyx Pharmaceuticals has received a positive vote from the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee, with a 7:2 vote supporting the approval of AMX0035 for treating ALS. If approved, it will be the first treatment to show significant slowing of disease progression and functional decline in ALS. The final decision from the FDA is expected by September 29, 2022. The clinical trial data for AMX0035 indicated potential benefits in overall survival and was well tolerated, with the CENTAUR trial meeting its primary efficacy endpoint.
Amylyx Pharmaceuticals announced that Nasdaq has halted trading of its common stock in conjunction with the second FDA Advisory Committee meeting regarding the NDA for AMX0035, aimed at treating ALS. This meeting is crucial for reviewing AMX0035, previously discussed on March 30, 2022. The FDA's target action date for this application is set for September 29, 2022. The company emphasizes its commitment to the neurodegenerative community through innovative treatments.
Amylyx Pharmaceuticals announced the reconvened meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) by the FDA to review the New Drug Application (NDA) for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS). Scheduled for September 7, 2022, this follows a previous meeting on March 30, 2022. The NDA's target action date is September 29, 2022, which was extended for further analysis of clinical data. AMX0035 is under regulatory review in the U.S. and EU, and is already approved in Canada as ALBRIOZA™.
Amylyx Pharmaceuticals (AMLX) announced the launch of ALBRIOZA™ (AMX0035) in Canada, marking its first commercial product. The FDA has scheduled an advisory meeting on September 7, 2022, regarding the NDA for AMX0035 for ALS, with a PDUFA action date set for September 29, 2022. Financial results for Q2 2022 show a net loss of $54.1 million, up from $21.9 million year-over-year, primarily due to increased R&D and administrative costs. Cash reserves stood at $206.7 million as of June 30, 2022, indicating ongoing funding for development and launch activities.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced the U.S. FDA's Peripheral and Central Nervous System Drugs Advisory Committee will reconvene on September 7, 2022, to review the New Drug Application (NDA) for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS). The review follows a previous meeting on March 30, 2022, and the FDA's extension of the PDUFA target action date from June 29 to September 29, 2022. The company emphasizes the urgent need for effective ALS treatments and is confident in the clinical data supporting AMX0035's benefits.
Amylyx Pharmaceuticals announced the commercial availability of ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) in Canada for ALS patients. This oral therapy may reduce neuronal cell death and was shown to significantly slow disease progression in clinical trials. Amylyx is actively pursuing reimbursement options with various Canadian health organizations to ensure patient access. CEO Tammy Moore emphasized the importance of equitable access to ALBRIOZA for Canadians living with ALS. The drug is also under review for marketing in the US and EU.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced a two-year research agreement with Sunnybrook Research Institute to discover Bax and Bak inhibitor candidates for treating ALS and other neurodegenerative diseases. The collaboration aims to expedite the identification of therapeutic candidates through biochemical and in vivo studies. Promising preclinical results suggest that targeted inhibition of these proteins may preserve motor neurons and improve survival rates in ALS models. Amylyx will have rights to license successful drug candidates post-research.
Amylyx Pharmaceuticals has announced a poster presentation on its Phase 3 PHOENIX trial for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS). Scheduled for July 9, 2022, at the International Congress on Neuromuscular Diseases in Brussels, the poster will detail the trial's design and methodology and discuss plans for an open-label extension phase. The ongoing trial aims to enroll a broader ALS population compared to the previous CENTAUR trial, providing additional data on AMX0035's effects.
Amylyx Pharmaceuticals has announced that the FDA is planning to reconvene the Peripheral and Central Nervous System Drugs Advisory Committee to discuss the NDA for AMX0035, a treatment for ALS, on September 7, 2022. This follows the FDA's extension of the PDUFA target action date to September 29, 2022. The meeting will focus on additional analyses from clinical studies, which aim to support the reported benefits of AMX0035. The drug is currently approved for ALS in Canada under the brand name ALBRIOZA.